Prevalence of aspirin resistance in patients with type 2 diabetes

Acta Diabetologica

Volumn 42, Issue 2, 2005, Pages 99-103

  Fateh Moghadam, S ^a   Plockinger U ^a   Cabeza, N ^b   Htun, P ^a   Reuter, T ^a   Ersel, S ^a   Gawaz, M ^b   Dietz, R ^a   Bocksch, W ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Aspirin resistance; Diabetes mellitus type 2; Platelet function

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; COLLAGEN;

ADULT; AGED; ANALYZER; ARTICLE; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GROUPS BY AGE; HEART PROTECTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; THERAPY RESISTANCE; THROMBOCYTE FUNCTION; THROMBOGENESIS;

ASPIRIN; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG RESISTANCE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PREVALENCE; SMOKING;

EID: 21144451858     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-005-0186-y     Document Type: Article

References (27)

1. Ruderman NB, Haudenschild C (1984) Diabetes as an atherogenic factor. Prog Cardiovasc Dis 26:373-412
2. Nathan DM (1993) Long-term complications of diabetes mellitus. N Engl J Med 328:1676-1685
3. Aronson D, Bloomgarden Z, Rayfield EJ (1996) Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 27:528-535
4. Donatelli M, Hoffmann E, Colletti I et al (1996) Circulating endothelin-1 levels in type 2 diabetic patients with ischaemic heart disease. Acta Diabetol 33:246-248
5. Williams SB, Goldfine AB, Timimi FK (1998) Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 97:1695-1701
6. Colwell JA, Nesto RW (2003) The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 26:2181-2188
7. Tschoepe D, Roesen P, Kaufmann L et al (1990) Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest 20:166-170
8. Knobler H, Savion N, Shenkman B et al (1998) Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. Thromb Res 90:181-190
9. Antithrombotic Trialist's Collaboration (2002) Collaboration meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86
10. The Physicians' Health Study (1988) Aspirin for the primary prevention of myocardial infarction. N Engl J Med 318:924-926
11. ETDRS Investigators (1992) Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study report 14. JAMA 268:1292-1300
12. Patrono C (2003) Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 1:1710-1713
13. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41:961-965
14. Gum PA, Kottke-Marchant K, Poggio ED et al (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88:230-235
15. Helgason CM, Tortorice KL, Winkler SR (1993) Aspirin response and failure in cerebral infarction. Stroke 24:345-350
16. Pappas JM, Westengard JC, Bull BS (1994) Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Lab Med 118:801-804
17. Grotemeyer KH (1991) Effects of acetylsalicylic acid in stroke patients. Evidence of non responders in a subpopulation of treated patients. Thromb Res 63:587-593
18. Chamorro A, Blanc R, Ascaso C, Saiz A, Vila N (1997) Factors associated to aspirin failure for secondary stroke prevention. Med Clin 109:569-572
19. Grotemeyer KH (1991) Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 63:587-593
20. Buchanan MR, Brister SJ (1995) Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 11:221-227
21. Helgason CM, Bolin KM, Hoff JA et al (1994) Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25:2331-2336
22. Mueller MR, Salat A, Stangl P et al (1997) Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 78:1003-1007
23. Grotemeyer KH, Scharafinski HW, Husstedt IW (1993) Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 71:397-403
24. Grundmann K, Jaschonek K, Kleine B et al (2003) Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 250:63-66
25. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A; PPP Collaborative Group (2003) Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients, results of the primary prevention project (PPP) trial. Diabetes Care 26:3264-3272
26. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502
27. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ: CREDO Investigators (2002) Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:2411-2420